Neuland Laboratories · NSE: NEULANDLAB · BSE: 524558
Q4 FY22 results · Jan–Mar 2022
Neuland Laboratories reported revenue from operations of ₹255.87 crore (up 4.6% from Q4 FY21) and net profit of ₹21.78 crore (up 26.0% from Q4 FY21) for Q4 FY22 (Jan–Mar 2022), on a consolidated basis.
| Item | Q4 FY22 | Q4 FY21 | YoY | Q3 FY22 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 255.87 | 244.70 | +4.6% | 236.47 | +8.2% |
| Other income | 0.63 | 14.60 | −95.7% | 1.90 | −66.8% |
| Total income | 256.50 | 259.30 | −1.1% | 238.37 | +7.6% |
| Profit before tax | 24.28 | 24.39 | −0.5% | 18.24 | +33.1% |
| Net profit for the period | 21.78 | 17.29 | +26.0% | 12.94 | +68.4% |
| EPS, basic (₹) | 17.01 | 13.48 | +26.2% | 10.08 | +68.8% |
| Net margin (%) | 8.5 | 7.1 | 5.5 |
| Item | Q4 FY22 | Q4 FY21 | YoY | Q3 FY22 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 255.87 | 244.70 | +4.6% | 236.47 | +8.2% |
| Other income | 0.63 | 14.60 | −95.7% | 1.90 | −66.8% |
| Total income | 256.50 | 259.30 | −1.1% | 238.37 | +7.6% |
| Profit before tax | 24.12 | 24.32 | −0.8% | 18.10 | +33.3% |
| Net profit for the period | 21.83 | 17.23 | +26.7% | 12.73 | +71.4% |
| EPS, basic (₹) | 17.01 | 13.43 | +26.7% | 9.92 | +71.4% |
| Net margin (%) | 8.5 | 7.0 | 5.4 |
Consolidated
- Filed with BSE
- 12 May 2022, 09:22 IST
- Board meeting
- 10 May 2022
- Period
- 01 Jan 2022 to 31 Mar 2022
- Review status
- Audited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 12 May 2022, 09:22 IST
- Board meeting
- 10 May 2022
- Period
- 01 Jan 2022 to 31 Mar 2022
- Review status
- Audited
- Source
- XBRL filing on BSE